NEW YORK, Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.There is no cost or obligation to you.
Covetrus, Inc.(NASDAQ: CVET)
Class Period: February 8, 2019 – August 12, 2019
Lead Plaintiff Deadline: November 29, 2019
Join the action: https://www.zlk.com/pslra-1/covetrus-inc-loss-form?wire=3
The lawsuit alleges: Covetrus, Inc.made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company’s separation from Henry Schein.
To learn more about the Covetrus, Inc.class action contact [email protected] .
Overstock.com, Inc.
(NASDAQ: OSTK)
Class Period: May 9, 2019 – September 23, 2019
Lead Plaintiff Deadline: November 26, 2019
Join the action: https://www.zlk.com/pslra-1/overstock-com-inc-loss-form?wire=3
The lawsuit alleges: Overstock.com, Inc.made materially false and/or misleading statements and/or failed to disclose that: (a) it was not true that Overstock would be able to support the launch of its tZERO crypto currency with earnings or cash flow from its retail operations and that whatever marginal improvements defendants had made by cutting costs and engineering earnings could not be sustained so as to generate positive EBITDA or cash from operations necessary to support its crypto currency operations; (b) there were extreme additional risks and substantial volatility in the price of Company shares was foreseeable, given defendants’ undisclosed plan to offer its tZERO Preferred Share Dividend as a means to squeeze short sellers out of Overstock and to prevent them from holding legitimate positions in the Company; (c) there was a foreseeable likelihood that the Company’s ability to accomplish its intended short squeeze would embolden the SEC or even market participants, such as major brokerage houses, to act to prevent this market manipulation; (d) it was not true that Overstock contained adequate systems of internal operational or financial controls, such that Overstock’s quarterly reports filed with the SEC were true, accurate or reliable; (e) as a result of the foregoing, it also was not true that the Company’s quarterly reports filed with the SEC were prepared in accordance with GAAP ad SEC rules; and (f) as a result of the aforementioned adverse conditions which defendants failed to disclose, defendants lacked any reasonable basis to claim that Overstock was operating according to plan, or that Overstock could achieve guidance sponsored and/or endorsed by defendants.
To learn more about the Overstock.com, Inc.
class action contact [email protected] .
Myriad Genetics, Inc.(NASDAQ: MYGN)
Class Period: September 2, 2016 – August 13, 2019
Lead Plaintiff Deadline: November 26, 2019
Join the action: https://www.zlk.com/pslra-1/myriad-genetics-inc-loss-form?wire=3
The lawsuit alleges: Myriad Genetics, Inc.made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S.Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company’s revenue; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the Myriad Genetics, Inc.
class action contact [email protected] .
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff.Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C.The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders.Attorney advertising.
Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E.Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com.
